Biogipuzkoa
Centro de investigación
Université Denis Diderot
París, FranciaPublicaciones en colaboración con investigadores/as de Université Denis Diderot (7)
2019
-
Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years
Scientific Reports, Vol. 9, Núm. 1
-
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Antiviral Research, Vol. 170
2018
-
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
The Lancet HIV, Vol. 5, Núm. 1, pp. e23-e34
-
Prosthetic Valve Candida spp. Endocarditis: New Insights into Long-term Prognosis-The ESCAPE Study
Clinical Infectious Diseases, Vol. 66, Núm. 6, pp. 825-832
2016
-
Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe
Clinical Infectious Diseases, Vol. 62, Núm. 5, pp. 655-663
2015
-
Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism
Medicine (United States), Vol. 94, Núm. 32
-
Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?
PLoS ONE, Vol. 10, Núm. 6